ReviewClinical ophthalmology (Auckland, N.Z.)2015
Strategies for improving early detection and diagnosis of neovascular age-related macular degeneration.
Review in Clinical ophthalmology (Auckland, N.Z.), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A Circulating MicroRNA Profile in a Laser-Induced Mouse Model of Choroidal Neovascularization.International journal of molecular sciences · 2020Pooled it
- Stage-associated immunoproteomic profiling of serum autoantibody-captured retinal antigens in age-related macular degeneration.Frontiers in immunology · 2026Article
- Differential Visual Outcomes in Neovascular AMD Based on Ellipsoid Zone Integrity and Fluid Presence: Insights from a Phase III Trial.Diagnostics (Basel, Switzerland) · 2025Article
- Analysis of the etiology, clinical characteristics and treatment outcomes of choroidal neovascularization in Chinese children and adolescents.BMC ophthalmology · 2025Article
- Home vision monitoring in patients with maculopathy: current and future options for digital technologies.Eye (London, England) · 2023Review
- Article
- Tele-ophthalmology for age-related macular degeneration during the COVID-19 pandemic and beyond.Journal of telemedicine and telecare · 2022Article
- Eligibility for faricimab in a real-world neovascular age-related macular degeneration population: a cross-sectional study.BMJ open · 2022Article
- Real-Life Value of the OdysightJournal of clinical medicine · 2022Article
- The Effect of Age-Related Macular Degeneration on Components of Face Perception.Investigative ophthalmology & visual science · 2020Article
- Moorfields AMD database report 2: fellow eye involvement with neovascular age-related macular degeneration.The British journal of ophthalmology · 2020Article
- CURRENT CONCEPTS AND MODALITIES FOR MONITORING THE FELLOW EYE IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: An Expert Panel Consensus.Retina (Philadelphia, Pa.) · 2020Review
- Risk-based Algorithm-guided Treatment Protocol for the Management of Neovascular Age-related Macular DegenerationTurkish journal of ophthalmology · 2019Article
- Reliability and diagnostic performance of a novel mobile app for hyperacuity self-monitoring in patients with age-related macular degeneration.Eye (London, England) · 2019Article
- Imaging Characteristics of Choroidal Neovascular Lesions in the AREDS2-HOME Study: Report Number 4.Ophthalmology. Retina · 2019Article
- Scotopic contour and shape discrimination using radial frequency patterns.Journal of vision · 2019Article
- [Reasons for delayed and discontinued therapy in age-related macular degeneration].Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft · 2018Article
- Baseline Predictors for Five-Year Visual Acuity Outcomes in the Comparison of AMD Treatment Trials.Ophthalmology. Retina · 2018Article
- Real-world use of ranibizumab for neovascular age-related macular degeneration in Taiwan.Scientific reports · 2018Article
- A Tablet-Based Retinal Function Test in Neovascular Age-Related Macular Degeneration Eyes and At-Risk Fellow Eye.Translational vision science & technology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Treatment of the neovascular form of age-related macular degeneration (AMD) has been revolutionized by the introduction of such agents as ranibizumab, bevacizumab, and aflibercept. As a result, the incidence of legal blindness occurring secondary to AMD has fallen dramatically in recent years in many countries. While these agents have undoubtedly been successful in reducing visual impairment and blindness, patients with neovascular AMD typically lose some vision over time, and often lose the ability to read, drive, or perform other important activities of daily living. Efforts are therefore under way to develop strategies that allow for earlier detection and treatment of this disease. In this review, we begin by providing an overview of the rationale for, and the benefits of, early detection and treatment of neovascular AMD. To achieve this, we begin by providing an overview of the pathophysiology and natural history of choroidal neovascularization, before reviewing the evidence from both clinical trials and "real-world" outcome studies. We continue by highlighting an area that is often overlooked: the importance of patient education and awareness for early AMD detection. We conclude the review by reviewing an array of both established and emerging technologies for early detection of choroidal neovascularization, ranging from Amsler chart testing, to hyperacuity testing, to advanced imaging techniques, such as optical coherence tomography.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.